The Utility of Functionally Relevant Signature Genes in Assessing the Clinical Outcomes of Dupilumab Treatment

Conditions

• Atopic Dermatitis
• Eczema

Eligibility Criteria

Sex

ALL

Age

19 Years - 75 Years

Healthy Volunteers

Not accepted

Interventions

• Dupilumab Prefilled Syringe — BIOLOGICAL
  open-label

Study Details

The utility of functionally relevant signature genes in assessing the clinical outcomes of dupilumab treatment in the adult onset atopic dermatitis

Key Dates

Start date

Sep 1, 2020

Status verified

Feb 2023

Primary completion

Nov 18, 2022

Completion

Nov 18, 2022

Study Design

Enrollment

12 participants (actual)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Other: open-label
  open-label

Primary Outcome Measure

The primary objective of this study is to correlate cutaneous transcriptomes with before and after Dupilumab treatment outcomes in patients who meet the clinical diagnostic criteria for adult onset AD. [ Time Frame: after 6 months ]

Locations (1)

Find similar trials in Cincinnati, OH

Related Studies

• A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
  PHASE3 · Enrolling By Invitation · Eli Lilly and Company · Birmingham, Alabama
• A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
  PHASE2 · Recruiting · Pfizer · Birmingham, Alabama
• A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
  PHASE3 · Recruiting · AbbVie · Little Rock, Arkansas
• Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)
  PHASE1 · Recruiting · National Institute of Allergy and Infectious Diseases (NIAID) · San Diego, California